177 related articles for article (PubMed ID: 38355560)
1. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Amara CS; Kami Reddy KR; Yuntao Y; Chan YS; Piyarathna DWB; Dobrolecki LE; Shih DJH; Shi Z; Xu J; Huang S; Ellis MJ; Apolo AB; Ballester LY; Gao J; Hansel DE; Lotan Y; Hodges HC; Lerner SP; Creighton CJ; Sreekumar A; Zheng WJ; Msaouel P; Kavuri SM; Putluri N
Nat Commun; 2024 Feb; 15(1):1373. PubMed ID: 38355560
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.
Gupta S; Albertson D; Gaston D; Heilbrun ME; Agarwal N; Boucher K; Parnell TJ; Liu T; Morgans A; Madison R; Gowen K; Miller VA; Ross JS; Ali SM; Millis SZ
Clin Genitourin Cancer; 2018 Apr; 16(2):e373-e382. PubMed ID: 28974397
[TBL] [Abstract][Full Text] [Related]
3. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
Siersbæk R; Scabia V; Nagarajan S; Chernukhin I; Papachristou EK; Broome R; Johnston SJ; Joosten SEP; Green AR; Kumar S; Jones J; Omarjee S; Alvarez-Fernandez R; Glont S; Aitken SJ; Kishore K; Cheeseman D; Rakha EA; D'Santos C; Zwart W; Russell A; Brisken C; Carroll JS
Cancer Cell; 2020 Sep; 38(3):412-423.e9. PubMed ID: 32679107
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
[TBL] [Abstract][Full Text] [Related]
5. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
Jing B; Wang T; Sun B; Xu J; Xu D; Liao Y; Song H; Guo W; Li K; Hu M; Zhang S; Ling J; Kuang Y; Zhang T; Zhou BP; Yao F; Deng J
Cancer Res; 2020 Feb; 80(4):784-797. PubMed ID: 31848193
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
8. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.
Chang Q; Bournazou E; Sansone P; Berishaj M; Gao SP; Daly L; Wels J; Theilen T; Granitto S; Zhang X; Cotari J; Alpaugh ML; de Stanchina E; Manova K; Li M; Bonafe M; Ceccarelli C; Taffurelli M; Santini D; Altan-Bonnet G; Kaplan R; Norton L; Nishimoto N; Huszar D; Lyden D; Bromberg J
Neoplasia; 2013 Jul; 15(7):848-62. PubMed ID: 23814496
[TBL] [Abstract][Full Text] [Related]
9. Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer.
Hong SH; Son KH; Ha SY; Wee TI; Choi SK; Won JE; Han HD; Ro Y; Park YM; Eun JW; Nam SW; Han JW; Kang K; You JS
Cancer Res; 2021 Jan; 81(2):356-370. PubMed ID: 33239431
[TBL] [Abstract][Full Text] [Related]
10. circBGN accelerates gastric cancer cell proliferation and invasion via activating IL6/STAT3 signaling pathway.
Li C; Peng X; Peng Z; Yan B
FASEB J; 2022 Nov; 36(11):e22604. PubMed ID: 36250950
[TBL] [Abstract][Full Text] [Related]
11. SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors.
Jeibmann A; Schulz J; Eikmeier K; Johann PD; Thiel K; Tegeder I; Ambrée O; Frühwald MC; Pfister SM; Kool M; Paulus W; Hasselblatt M
J Neurooncol; 2017 Feb; 131(3):477-484. PubMed ID: 28108836
[TBL] [Abstract][Full Text] [Related]
12. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
13. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
14. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
[TBL] [Abstract][Full Text] [Related]
15. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract][Full Text] [Related]
16. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
17. Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.
Li M; Shen Y; Xiong Y; Wang S; Li C; Bai J; Zhang Y
Cell Prolif; 2021 Dec; 54(12):e13136. PubMed ID: 34668612
[TBL] [Abstract][Full Text] [Related]
18. Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p.
Xia Y; Chen S; Cui J; Wang Y; Liu X; Shen Y; Gong L; Jiang X; Wang W; Zhu Y; Sun S; Li J; Zou Y; Shi B
Biochem Pharmacol; 2021 Jun; 188():114575. PubMed ID: 33887260
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.
Griesinger AM; Josephson RJ; Donson AM; Mulcahy Levy JM; Amani V; Birks DK; Hoffman LM; Furtek SL; Reigan P; Handler MH; Vibhakar R; Foreman NK
Cancer Immunol Res; 2015 Oct; 3(10):1165-74. PubMed ID: 25968456
[TBL] [Abstract][Full Text] [Related]
20. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
